LONDON – A government-mandated study of how to accelerate access to new drugs will recommend that a select group of highly innovative products be singled out for special treatment, with plans agreed during development to take them all the way through regulatory approval, health technology assessment and commissioning at scale in the U.K.'s single payer National Health System (NHS).